Drugmakers Sue To Block HHS’ Certification Of Clinics Under 340B Drug Pricing Program

Bloomberg Law (12/23, Phengsitthy, Subscription Publication) reports, “Pharmaceutical giants are seeking to block a federal health agency’s certification and recertification of clinics treating sexually transmitted diseases to receive steeply discounted medicines under a federal drug discount program.” The companies, “Amgen Inc., Eli Lilly & Co., and UCB Inc. are challenging approvals from the US Department of Health and Human Services that allow certain clinics to obtain discounted drugs from manufacturers under the federal 340B Drug Pricing Program, according to a complaint filed Dec. 20 in the US District Court for the District of Columbia.”